• Helen W. BoucherEmail author
  • Thomas F. Patterson
Part of the Infectious Disease book series (ID)


Aspergillus, a hyaline mold, causes a variety of clinical conditions ranging from colonization to invasive pulmonary aspergillosis. Immunocompromised patients, including those with hematologic malignancy, stem cell, or solid organ transplantation, are most often affected and mortality due to invasive aspergillosis remains high even with advances in antifungal therapy and management. Successful therapy depends not only on an early diagnosis—which is often difficult to establish—but, even more importantly, on reversal of underlying host immune defects, such as neutropenia or high-dose immunosuppressive therapy. Nonculture-based tests and radiological approaches can be used to establish an early diagnosis of infection and may result in improved outcomes of infection. Even when a therapy begins promptly, efficacy of the therapy is poor, particularly in patients with disseminated or central nervous system disease. Recent developments include more widespread use of newer diagnostic approaches and improved understanding of how best to use available antifungal agents.


Aspergillus species Invasive aspergillosis Immunocompromised Galactomannan Voriconazole Amphotericin Echinocandin 


  1. 1.
    Patterson TF. Aspergillus species. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 7th ed. Philadelphia: Elsevier; 2010. p. 3241–55.Google Scholar
  2. 2.
    Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of america. Clin Infect Dis. 2008 Feb 1;46(3):327–60.PubMedGoogle Scholar
  3. 3.
    Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32(3):358–66.PubMedGoogle Scholar
  4. 4.
    McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, et al. Trends in mortality due to invasive mycotic diseases in the united states, 1980–1997. Clin Infect Dis. 2001 Sep 1;33(5):641–7.PubMedGoogle Scholar
  5. 5.
    Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, et al. Invasive aspergillosis. disease spectrum, treatment practices, and outcomes. I3 aspergillus study group. Medicine (Baltimore). 2000 Jul;79(4):250–60.Google Scholar
  6. 6.
    Caillot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol. 1997 Jan;15(1):139–47.PubMedGoogle Scholar
  7. 7.
    Maertens J, Vrebos M, Boogaerts M. Assessing risk factors for systemic fungal infections. Eur J Cancer Care (Engl). 2001 Mar;10(1):56–62.Google Scholar
  8. 8.
    Patterson TF. Advances and challenges in management of invasive mycoses. Lancet. 2005 Sep 17–23;366(9490):1013–25.PubMedGoogle Scholar
  9. 9.
    Hajjeh RA, Warnock DW. Counterpoint: invasive aspergillosis and the environment–rethinking our approach to prevention. Clin Infect Dis. 2001 Nov 1;33(9):1549–52.PubMedGoogle Scholar
  10. 10.
    Woodcock AA, Steel N, Moore CB, Howard SJ, Custovic A, Denning DW. Fungal contamination of bedding. Allergy. 2006 Jan;61(1):140–2.PubMedGoogle Scholar
  11. 11.
    Anaissie EJ, Stratton SL, Dignani MC, Lee CK, Summerbell RC, Rex JH, et al. Pathogenic molds (including aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. Blood. 2003 Apr 1;101(7):2542–6.PubMedGoogle Scholar
  12. 12.
    Iwen PC, Rupp ME, Langnas AN, Reed EC, Hinrichs SH. Invasive pulmonary aspergillosis due to aspergillus terreus: 12-year experience and review of the literature. Clin Infect Dis. 1998 May;26(5):1092–7.PubMedGoogle Scholar
  13. 13.
    Baddley JW, Andes DR, Marr KA, Kontoyiannis DP, Alexander BD, Kauffman CA, et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis. 2010 Jun 15;50(12):1559–67.PubMedCentralPubMedGoogle Scholar
  14. 14.
    Warris A, Bjørneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med. 2001;344(14):1099.PubMedGoogle Scholar
  15. 15.
    Walsh TJ, Petraitis V, Petraitiene R, Field-Ridley A, Sutton D, Ghannoum M, et al. Experimental pulmonary aspergillosis due to aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis. 2003 Jul 15;188(2):305–19.PubMedGoogle Scholar
  16. 16.
    Brummer E, Kamberi M, Stevens DA. Regulation by granulocyte-macrophage colony-stimulating factor and/or steroids given in vivo of proinflammatory cytokine and chemokine production by bronchoalveolar macrophages in response to aspergillus conidia. J Infect Dis. 2003 Feb 15;187(4):705–9.PubMedGoogle Scholar
  17. 17.
    Kan VL, Bennett JE. Lectin-like attachment sites on murine pulmonary alveolar macrophages bind aspergillus fumigatus conidia. J Infect Dis. 1988 Aug;158(2):407–14.PubMedGoogle Scholar
  18. 18.
    Levitz SM, Selsted ME, Ganz T, Lehrer RI, Diamond RD. In vitro killing of spores and hyphae of aspergillus fumigatus and rhizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages. J Infect Dis. 1986 Sep;154(3):483–9.PubMedGoogle Scholar
  19. 19.
    Washburn RG, Gallin JI, Bennett JE. Oxidative killing of aspergillus fumigatus proceeds by parallel myeloperoxidase-dependent and -independent pathways. Infect Immun. 1987 Sep;55(9):2088–92.PubMedCentralPubMedGoogle Scholar
  20. 20.
    Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev. 1999;12:310–50.PubMedCentralPubMedGoogle Scholar
  21. 21.
    Stanzani M, Orciuolo E, Lewis R, Kontoyiannis DP, Martins SL, St John LS, et al. Aspergillus fumigatus suppresses the human cellular immune response via gliotoxin-mediated apoptosis of monocytes. Blood. 2005 Mar 15;105(6):2258–65.PubMedGoogle Scholar
  22. 22.
    Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 2002 Nov;110(5):685–92.PubMedGoogle Scholar
  23. 23.
    Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis–state of the art: cystic fibrosis foundation consensus conference. Clin Infect Dis. 2003 Oct 1;37(Suppl 3):S225–64.PubMedGoogle Scholar
  24. 24.
    Patterson R, Greenberger PA, Radin RC, Roberts M. Allergic bronchopulmonary aspergillosis: staging as an aid to management. Ann Intern Med. 1982 Mar;96(3):286–91.PubMedGoogle Scholar
  25. 25.
    Wark PA, Gibson PG, Wilson AJ. Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst Rev. 2003;3(3):CD001108.PubMedGoogle Scholar
  26. 26.
    Stevens DA, Schwartz HJ, Lee JY, Moskovitz BL, Jerome DC, Catanzaro A, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med. 2000 Mar 16;342(11):756–62.PubMedGoogle Scholar
  27. 27.
    Gillespie MB, O’Malley BW. An algorithmic approach to the diagnosis and management of invasive fungal rhinosinusitis in the immunocompromised patient. Otolaryngol Clin North Am. 2000 Apr;33(2):323–34.PubMedGoogle Scholar
  28. 28.
    Ferguson BJ. Fungus balls of the paranasal sinuses. Otolaryngol Clin North Am. 2000 Apr;33(2):389–98.PubMedGoogle Scholar
  29. 29.
    Kauffman CA. Quandary about treatment of aspergillomas persists. Lancet. 1996 Jun 15;347(9016):1640.PubMedGoogle Scholar
  30. 30.
    Kaur R, Mittal N, Kakkar M, Aggarwal AK, Mathur MD. Otomycosis: a clinicomycologic study. Ear Nose Throat J. 2000;79(8):606–9.PubMedGoogle Scholar
  31. 31.
    Torres-Rodriguez JM, Madrenys-Brunet N, Siddat M, Lopez-Jodra O, Jimenez T. Aspergillus versicolor as cause of onychomycosis: report of 12 cases and susceptibility testing to antifungal drugs. J Eur Acad Dermatol Venereol. 1998 Jul;11(1):25–31.PubMedGoogle Scholar
  32. 32.
    Kuo IC, Margolis TP, Cevallos V, Hwang DG. Aspergillus fumigatus keratitis after laser in situ keratomileusis. Cornea. 2001 Apr;20(3):342–4.PubMedGoogle Scholar
  33. 33.
    Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis. 2003 Oct 1;37(Suppl 3):S265–80.PubMedGoogle Scholar
  34. 34.
    Jain LR, Denning DW. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect. 2006 May;52(5):e133–7.PubMedGoogle Scholar
  35. 35.
    Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984 Mar;100(3):345–51.PubMedGoogle Scholar
  36. 36.
    Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002 Apr 1;34(7):909–17.PubMedGoogle Scholar
  37. 37.
    Miller WT, Jr, Sais GJ, Frank I, Gefter WB, Aronchick JM, Miller WT. Pulmonary aspergillosis in patients with AIDS. clinical and radiographic correlations. Chest. 1994 Jan;105(1):37–44.Google Scholar
  38. 38.
    Allo MD, Miller J, Townsend T, Tan C. Primary cutaneous aspergillosis associated with hickman intravenous catheters. N Engl J Med. 1987 Oct 29;317(18):1105–8.PubMedGoogle Scholar
  39. 39.
    Mylonakis E, Rich J, Skolnik PR, De Orchis DF, Flanigan T. Invasive aspergillus sinusitis in patients with human immunodeficiency virus infection. report of 2 cases and review. Medicine (Baltimore). 1997 Jul;76(4):249–55.Google Scholar
  40. 40.
    Ellis ME, Al-Abdely H, Sandridge A, Greer W, Ventura W. Fungal endocarditis: evidence in the world literature, 1965–1995. Clin Infect Dis. 2001 Jan;32(1):50–62.PubMedGoogle Scholar
  41. 41.
    Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis. 1990 Nov-Dec;12(6):1147–201.PubMedGoogle Scholar
  42. 42.
    De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the european organization for research and treatment of Cancer/Invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis. 2008 Jun 15;46(12):1813–21.PubMedCentralPubMedGoogle Scholar
  43. 43.
    Sutton DA, Fothergill AW, Rinaldi MG. Guide to clinically significant fungi. Baltimore: Lippincott Williams & Wilkins; 1998.Google Scholar
  44. 44.
    Caillot D, Couaillier JF, Bernard A, Casasnovas O, Denning DW, Mannone L, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol. 2001 Jan 1;19(1):253–9.PubMedGoogle Scholar
  45. 45.
    Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002 Aug 8;347(6):408–15.PubMedGoogle Scholar
  46. 46.
    Herbrecht R. Improving the outcome of invasive aspergillosis: new diagnostic tools and new therapeutic strategies. Ann Hematol. 2002;81(Suppl 2):S52–3.PubMedGoogle Scholar
  47. 47.
    Maertens J, Theunissen K, Verbeken E, Lagrou K, Verhaegen J, Boogaerts M, et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol. 2004 Sep;126(6):852–60.PubMedGoogle Scholar
  48. 48.
    Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005 Nov 1;41(9):1242–50.PubMedGoogle Scholar
  49. 49.
    Musher B, Fredricks D, Leisenring W, Balajee SA, Smith C, Marr KA. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol. 2004 Dec;42(12):5517–22.PubMedCentralPubMedGoogle Scholar
  50. 50.
    Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006 May 15;42(10):1417–27.PubMedGoogle Scholar
  51. 51.
    Loeffler J, Hebart H, Cox P, Flues N, Schumacher U, Einsele H. Nucleic acid sequence-based amplification of aspergillus RNA in blood samples. J Clin Microbiol. 2001 Apr;39(4):1626–9.PubMedCentralPubMedGoogle Scholar
  52. 52.
    White PL, Linton CJ, Perry MD, Johnson EM, Barnes RA. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis. 2006;42(4):479–86.PubMedGoogle Scholar
  53. 53.
    Donnelly JP. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go. Clin Infect Dis. 2006;42(4):487–9.PubMedGoogle Scholar
  54. 54.
    Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly JP. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis. 2009 Feb;9(2):89–96.PubMedGoogle Scholar
  55. 55.
    Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (1– > 3)-beta-D-glucan assay for the diagnosis of invasive fungal infections–a study based on autopsy cases from 6 years. Clin Infect Dis. 2008 Jun 15;46(12):1864–70.PubMedGoogle Scholar
  56. 56.
    White PL, Bretagne S, Klingspor L, Melchers WJ, McCulloch E, Schulz B, et al. Aspergillus PCR: one step closer to standardization. J Clin Microbiol. 2010 Apr;48(4):1231–40.PubMedCentralPubMedGoogle Scholar
  57. 57.
    Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004 Jul 15;39(2):199–205.PubMedGoogle Scholar
  58. 58.
    Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, et al. Multicenter clinical evaluation of the (1– > 3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005 Sep 1;41(5):654–9.PubMedGoogle Scholar
  59. 59.
    Mennink-Kersten MA, Warris A, Verweij PE. 1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med. 2006 Jun 29;354(26):2834–5.PubMedGoogle Scholar
  60. 60.
    Mennink-Kersten MA, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity. Clin Infect Dis. 2008 Jun 15;46(12):1930–1.PubMedGoogle Scholar
  61. 61.
    Mennink-Kersten MA, Verweij PE. Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin North Am. 2006 Sep;20(3):711,27, viii.Google Scholar
  62. 62.
    Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis. 2003 Oct 1;37(Suppl 3):S157–87.PubMedGoogle Scholar
  63. 63.
    Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs. 2004;64(18):1997–2020.PubMedGoogle Scholar
  64. 64.
    Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia. 2001;150(3):101–15.PubMedGoogle Scholar
  65. 65.
    Vadnerkar A, Nguyen MH, Mitsani D, Crespo M, Pilewski J, Toyoda Y, et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant. 2010 Nov;29(11):1240–4.PubMedGoogle Scholar
  66. 66.
    Zwald FO, Spratt M, Lemos BD, Veledar E, Lawrence C, Marshall Lyon G, et al. Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. Dermatol Surg. 2012 Aug;38(8):1369–74.PubMedGoogle Scholar
  67. 67.
    Wermers RA, Cooper K, Razonable RR, Deziel PJ, Whitford GM, Kremers WK, et al. Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis. 2011 Mar 1;52(5):604–11.PubMedGoogle Scholar
  68. 68.
    Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. 2012 Oct;55(8):1080–7.PubMedGoogle Scholar
  69. 69.
    Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008 Jan 15;46(2):201–11.PubMedGoogle Scholar
  70. 70.
    Caillot D. Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis. Acta Haematol. 2003;109(3):111–8.PubMedGoogle Scholar
  71. 71.
    Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007 Jan 1;44(1):2–12.PubMedGoogle Scholar
  72. 72.
    Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev. 1999 Jan;12(1):40–79.PubMedCentralPubMedGoogle Scholar
  73. 73.
    Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. J Antimicrob Chemother. 2002;49(2):353–7.PubMedGoogle Scholar
  74. 74.
    Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis. 2001 Mar 1;32(5):686–93.PubMedGoogle Scholar
  75. 75.
    Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis. 1999 Dec;29(6):1402–7.PubMedGoogle Scholar
  76. 76.
    Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998 Jun;26(6):1383–96.PubMedGoogle Scholar
  77. 77.
    Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother. 2001 Dec;45(12):3487–96.PubMedCentralPubMedGoogle Scholar
  78. 78.
    Rex JH, Walsh TJ, Nettleman M, Anaissie EJ, Bennett JE, Bow EJ, et al. Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis. 2001 Jul 1;33(1):95–106.PubMedGoogle Scholar
  79. 79.
    Barrett JP, Vardulaki KA, Conlon C, Cooke J, Daza-Ramirez P, Evans EG, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther. 2003 May;25(5):1295–320.PubMedGoogle Scholar
  80. 80.
    Leenders AC, Daenen S, Jansen RL, Hop WC, Lowenberg B, Wijermans PW, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol. 1998 Oct;103(1):205–12.PubMedGoogle Scholar
  81. 81.
    Bowden R, Chandrasekar P, White MH, Li X, Pietrelli L, Gurwith M, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2002 Aug 15;35(4):359–66.PubMedGoogle Scholar
  82. 82.
    Trullas JC, Cervera C, Benito N, de la Bellacasa JP, Agusti C, Rovira M, et al. Invasive pulmonary aspergillosis in solid organ and bone marrow transplant recipients. Transplant Proc. 2005 Nov;37(9):4091–3.PubMedGoogle Scholar
  83. 83.
    Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007 May 15;44(10):1289–97.PubMedGoogle Scholar
  84. 84.
    Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004 Dec 1;39(11):1563–71.PubMedGoogle Scholar
  85. 85.
    Marr KA, Hachem R, Papanicolaou G, Somani J, Arduino JM, Lipka CJ, et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis. 2004 Sep;6(3):110–6.PubMedGoogle Scholar
  86. 86.
    van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004 Nov 15;39(10):1407–16.PubMedGoogle Scholar
  87. 87.
    Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007 Jan 25;356(4):348–59.PubMedGoogle Scholar
  88. 88.
    Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007 Jan 25;356(4):335–47.PubMedGoogle Scholar
  89. 89.
    Bowman JC, Hicks PS, Kurtz MB, Rosen H, Schmatz DM, Liberator PA, et al. The antifungal echinocandin caspofungin acetate kills growing cells of aspergillus fumigatus in vitro. Antimicrob Agents Chemother. 2002 Sep;46(9):3001–12.PubMedCentralPubMedGoogle Scholar
  90. 90.
    Viscoli C. Combination therapy for invasive aspergillosis. Clin Infect Dis. 2004 Sep 15;39(6):803–5.PubMedGoogle Scholar
  91. 91.
    Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother. 2002 Aug;46(8):2564–8.PubMedCentralPubMedGoogle Scholar
  92. 92.
    Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004 Sep 15;39(6):797–802.PubMedGoogle Scholar
  93. 93.
    Aliff TB, Maslak PG, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, et al. Refractory aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer. 2003 Feb 15;97(4):1025–32.PubMedGoogle Scholar
  94. 94.
    Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003 Jul 15;98(2):292–9.PubMedGoogle Scholar
  95. 95.
    Marr KA, Schlamm H, Rottinghaus ST, et al. A randomised, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). 2012.Google Scholar
  96. 96.
    Yeghen T, Kibbler CC, Prentice HG, Berger LA, Wallesby RK, McWhinney PH, et al. Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution. Clin Infect Dis. 2000 Oct;31(4):859–68.PubMedGoogle Scholar
  97. 97.
    Patterson TF, Boucher HW, Herbrecht R, Denning DW, Lortholary O, Ribaud P, et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis. 2005 Nov 15;41(10):1448–52.PubMedGoogle Scholar
  98. 98.
    Keating GM. Posaconazole. Drugs. 2005;65(11):1553,67; discussion 1568–9.Google Scholar
  99. 99.
    Murdoch D, Plosker GL. Anidulafungin. Drugs. 2004;64(19):2249,58; discussion 2259–60.Google Scholar
  100. 100.
    Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis. 2003 Apr 15;36(8):943–51.PubMedGoogle Scholar
  101. 101.
    Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC collaborative study group. Clin Infect Dis. 2000 Nov;31(5):1155–63.PubMedGoogle Scholar
  102. 102.
    Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006 Nov;53(5):337–49.PubMedGoogle Scholar
  103. 103.
    Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003 Mar 1;36(5):630–7.Google Scholar

Suggested Reading

  1. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004;64:1997–2020.PubMedGoogle Scholar
  2. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997;15:139–147.PubMedGoogle Scholar
  3. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408–415.PubMedGoogle Scholar
  4. Keating GM. Posaconazole. Drugs 2005;65:1553–1567.PubMedGoogle Scholar
  5. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005;41:1242–1250.PubMedGoogle Scholar
  6. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004;39:797–802.PubMedGoogle Scholar
  7. Patterson TF. Aspergillus species. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Philadelphia, PA: Elsevier Churchill Livingstone, 2005;2958–2973.Google Scholar
  8. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005;366:1013–1025.PubMedGoogle Scholar
  9. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 2000;79:250–260.Google Scholar
  10. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000;30:696–709.PubMedGoogle Scholar
  11. Walsh TJ, Petraitis V, Petraitiene R, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis 2003;188:305–319.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Division of Infectious Diseases and Geographic MedicineTufts Medical CenterBostonUSA
  2. 2.Department of Medicine, Division of Infectious DiseasesUniversity of Texas Health Science Center at San Antonio; Audie L. Murphy Division, South Texas Veterans Health Care SystemSan AntonioUSA

Personalised recommendations